Staphyphage: Biorisk Reduction in MRSA Research

• Main Authors: Tan, Cheng Siang, Nurul Aqilah, Binti Aqiludeen, Gowbei, Annabel, Mijen Beemer, Alexander, Santhana, Raj L., SIti Fairouz, Binti Ibrahim
• Format: Conference or Workshop Item
• Language: English
• Published: 2017
• Subjects: QR355 Virology; RM Therapeutics. Pharmacology
• Online Access: http://ir.unimas.my/id/eprint/28776/1/Staphyphage%20poster.pdf; http://ir.unimas.my/id/eprint/28776/

Staphylococcus aureus is an opportunistic human pathogen that has the ability to cause both health care-associated and community-acquired infections [1]. It has been identified as one of the ‘high priority pathogen’ by the World Health Organization (WHO) [5] The infections were once, easily treated with antibiotics before resistance against beta-lactams (eg. Methicillin) and glycopeptides (eg. Vancomycin) began to emerge over the years and caused an increase in mortality and morbidity rates in patients infected with S. aureus [2,3]. This has led to an increased interest in the exploration of the use of bacteriophage as an alternative approach way to combat MRSA because a bacteriophage has bacteriolytic mechanism independent from those of any known antibiotics [5]. The availability of a virulent and broad spectrum bacteriophage against MRSA may significantly reduce the overall biorisk as it acts as an effective treatment in case of exposure.